Professor Andrew Shelling
BPhEd, BSc(Hons), PhD
Professor Shelling is head of the Medical Genetics Group. His research is primarily interested in understanding the molecular changes that occur during the development of genetic disorders, focusing on breast and ovarian cancer, and reproductive disorders. An understanding of the important changes will eventually provide an opportunity to improve the early detection of disease, and to target more effective treatment.
Andrew is extensively involved in teaching reproduction, genetics and cancer at the University of Auckland.
Andrew began at Otago University with a degree in Physical Education, and BSc (Hons) and PhD in Biochemistry. He was awarded the Nuffield Medical Fellowship in 1992, and spent three years in Oxford, UK, studying the genetics of ovarian cancer, before being appointed to Auckland University as a Lecturer. Andrew has served as Deputy Head of Department of Obstetrics and Gynaecology, President of the New Zealand branch of the Human Genetics Society of Australasia, Deputy-Chairperson of the Advisory Committee for Assisted Reproductive Technologies and as Associate Editor for the Human Reproduction journal. He is currently Director of the Bachelor of Medical Sciences Honours programme, on the Editorial Board for the Human Fertility journal and is a Trustee for the Nurture Foundation for Reproductive Research.
Andrew has been the Associate Dean (Research) at the Faculty of Medical and Health Sciences since 2013.
Research | Current
- Human genetics
- Cancer genetics
Associate Dean (Research)
Areas of expertise
Professor in Reproductive Science
Selected publications and creative works (Research Outputs)
- Lucas, N., Rosario, R., & Shelling, A. (2015). New Zealand University students' knowledge of fertility decline in women via natural pregnancy and assisted reproductive technologies. Human fertility (Cambridge, England), 18 (3), 208-214. 10.3109/14647273.2015.1006694
- Rosario, R., Cohen, P. A., & Shelling, A. N. (2014). The role of FOXL2 in the pathogenesis of adult ovarian granulosa cell tumours. Gynecologic Oncology, 133 (2), 382-387. 10.1016/j.ygyno.2013.12.012
- Rosario, R., Wilson, M., Cheng, W. T., Payne, K., Cohen, P. A., Fong, P., & Shelling, A. N. (2013). Adult granulosa cell tumours (GCT): Clinicopathological outcomes including FOXL2 mutational status and expression. Gynecologic Oncology, 131 (2), 325-329. 10.1016/j.ygyno.2013.08.031
Other University of Auckland co-authors: Michelle Wilson
- Shelling, A. N. (2012). Mutations in inhibin and activin genes associated with human disease. Molecular and Cellular Endocrinology, 359 (1-2), 113-120. 10.1016/j.mce.2011.07.031
- Rosario, R., Araki, H., Print, C. G., & Shelling, A. N. (2012). The transcriptional targets of mutant FOXL2 in granulosa cell tumours. PLoS One, 7 (9)10.1371/journal.pone.0046270
Other University of Auckland co-authors: Cris Print
- Shelling, A. N. (2010). Premature ovarian failure. Reproduction, 140 (5), 633-641. 10.1530/REP-09-0567
- Chand, A. L., Harrison, C. A., & Shelling, A. N. (2010). Inhibin and premature ovarian failure. Human Reproduction Update, 16 (1), 39-50. 10.1093/humupd/dmp031
- Ramachandran, A., Marshall, E. S., Love, D. R., Baguley, B. C., & Shelling, A. N. (2009). Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett, 285 (2), 157-165. 10.1016/j.canlet.2009.05.010
Other University of Auckland co-authors: Don Love, Bruce Baguley
- Media Contact
DDI 09 923 2402 (extn 82402)
M&HS BUILDING 505 - Bldg 505
Level 1, Room 101F
85 PARK RD